Immunocore posted Q2 net sales of $115.9 million, up 18% year over year, driven by higher volumes in the U.S. and international regions.
Net loss narrowed to $808,000, or $0.02 per share, from a $10.3 million loss a year earlier.
R&D expense rose to $73.9 million from $69 million, reflecting advancement of clinical programs including three Phase 3 studies.
Cash position and clinical progress
Cash, cash equivalents and marketable securities totaled $880 million at June 30, 2026, up from $864.2 million at Dec. 31, 2025.
Enrollment in the Phase 3 TEBE-AM trial in previously treated advanced cutaneous melanoma neared the 540-patient target, with topline data possible by end-2026.
IMCR•
